CStone Pharmaceuticals (HKG:2616)

Market Cap	13.01B
Revenue (ttm)	221.89M
Net Income (ttm)	-413.21M
Shares Out	1.46B
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	33.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,050,142
Average Volume	23,097,416
Open	9.28
Previous Close	8.88
Day's Range	8.74 - 9.28
52-Week Range	1.25 - 9.45
Beta	0.04
RSI	69.96
Earnings Date	Aug 21, 2025

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 135
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2616

Financial Performance

In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.

Financial numbers in CNY